Results 61 to 70 of about 1,673 (95)

Projected impact of Cervarix® vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom.

Hum Vaccin Immunother, 2014
Van Effelterre T, Hogea C, Taylor S.
europepmc   +1 more source

Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults. [PDF]

Hum Vaccin Immunother, 2014
Toft L, Tolstrup M, Müller M, Sehr P, Bonde J, Storgaard M, Østergaard L, Søgaard OS.   +7 more
europepmc   +1 more source

Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.

Vaccine, 2014
Bissett SL, Draper E, Myers RE, Godi A, Beddows S.   +4 more
europepmc   +1 more source

Serious adverse events following human papillomavirus vaccination: A systematic review and meta-analysis of post-marketing evidence. [PDF]

Hum Vaccin Immunother
Brown H, Nasreen S.
europepmc   +1 more source

Evaluation of an HPV16-L1 antibody rapid test for oropharyngeal cancer diagnosis: diagnostic accuracy and challenges in real-world settings. [PDF]

EBioMedicine
Kusters JMA, Brenner N, Bogaards JA, Silling S, El-Zein M, Gray P, Kann H, Franco EL, Lehtinen M, Dietz A, Laban S, Klussmann JP, Wieland U, Waterboer T.   +13 more
europepmc   +1 more source

Immunogenicity of one and two doses of Gardasil®9 in Tanzanian girls in the DoRIS Trial. [PDF]

NPJ Vaccines
Kemp TJ, Baisley K, Changalucha J, Indangasi J, Whitworth H, Lacey CJ, Mwanzalima D, Hashim R, Kapiga S, Hayes RJ, Pinto LA, Watson-Jones D.   +11 more
europepmc   +1 more source

Maximizing impact: the power of early HPV vaccination for long-term protection-lessons from a systematic review and meta-regression analysis. [PDF]

J Public Health (Oxf)
Navarro-Torné A, Aris E, Callegaro A, Benninghoff B, Yun H, Vetter V.   +5 more
europepmc   +1 more source

Post-approval safety studies of vaccines in pregnancy: available regulatory guidance and next steps towards the more efficient generation of safety evidence. [PDF]

Front Drug Saf Regul
MacDonald SC, Guignard AP, Munoz FM, Dareng EO, Davis KJ, Machado MAA, Shmuel S, Taddei L, Marcelon L.   +8 more
europepmc   +1 more source

Towards Global HPV Eradication: Single-Dose HPV Vaccination vs. Pseudoscience. [PDF]

Pathophysiology
Shiro R, Tsunoda I.
europepmc   +1 more source

Human Papillomavirus Vaccine immune responses in an Olive baboon model is not compromised by chronic <i>Schistosoma mansoni</i> infections. [PDF]

AIMS Microbiol
Obiero L, Songoro E, Omondi M, Nyakundi R, Ochola L.   +4 more
europepmc   +1 more source